Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Metreleptin

            Therapeutic Area: Genetic Disease Product Name: Myalepta

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Amryt Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 08, 2021

            Details:

            This agreement completes the multi-regional distribution agreements with Medison, announced in February, to distribute Myalept® (metreleptin) and Lojuxta® (lomitapide) in Israel, and Juxtapid® (lomitapide) in Canada.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Alpha1-Proteinase Inhibitor (Human)

            Therapeutic Area: Genetic Disease Product Name: Glassia

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement October 07, 2020

            Details:

            Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply Agreement.